AU2003231157C1 - Inositol pyrophosphates, and methods of use thereof - Google Patents

Inositol pyrophosphates, and methods of use thereof Download PDF

Info

Publication number
AU2003231157C1
AU2003231157C1 AU2003231157A AU2003231157A AU2003231157C1 AU 2003231157 C1 AU2003231157 C1 AU 2003231157C1 AU 2003231157 A AU2003231157 A AU 2003231157A AU 2003231157 A AU2003231157 A AU 2003231157A AU 2003231157 C1 AU2003231157 C1 AU 2003231157C1
Authority
AU
Australia
Prior art keywords
compound
ihp
instance
hemoglobin
ammonium ions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003231157A
Other languages
English (en)
Other versions
AU2003231157B2 (en
AU2003231157A1 (en
Inventor
Konstantina Fylaktakidou
Ruth Greferath
Jean Marie Lehn
Yves Claude Nicolau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Strasbourg
NormOxys Inc
Original Assignee
Universite de Strasbourg
NormOxys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Strasbourg, NormOxys Inc filed Critical Universite de Strasbourg
Publication of AU2003231157A1 publication Critical patent/AU2003231157A1/en
Assigned to OXYPLUS, INC. reassignment OXYPLUS, INC. Request for Assignment Assignors: GMP OXYCELL, INC.
Publication of AU2003231157B2 publication Critical patent/AU2003231157B2/en
Assigned to OXYPLUS, INC., UNIVERSITE LOUIS PASTEUR DE STRASBOURG reassignment OXYPLUS, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: OXYPLUS, INC.
Assigned to UNIVERSITE LOUIS PASTEUR DE STRASBOURG, NORMOXYS, INC. reassignment UNIVERSITE LOUIS PASTEUR DE STRASBOURG Alteration of Name(s) of Applicant(s) under S113 Assignors: OXYPLUS, INC., UNIVERSITE LOUIS PASTEUR DE STRASBOURG
Priority to AU2009200042A priority Critical patent/AU2009200042A1/en
Publication of AU2003231157C1 publication Critical patent/AU2003231157C1/en
Application granted granted Critical
Assigned to NORMOXYS, INC., UNIVERSITE DE STRASBOURG reassignment NORMOXYS, INC. Request to Amend Deed and Register Assignors: NORMOXYS, INC., UNIVERSITE DE STRASBOURG, UNIVERSITE LOUIS PASTEUR DE STRASBOURG
Assigned to NORMOXYS, INC., UNIVERSITE DE STRASBOURG reassignment NORMOXYS, INC. Request to Amend Deed and Register Assignors: NORMOXYS, INC., UNIVERSITE DE STRASBOURG, UNIVERSITE LOUIS PASTEUR DE STRASBOURG
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65746—Esters of oxyacids of phosphorus the molecule containing more than one cyclic phosphorus atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
AU2003231157A 2002-04-29 2003-04-29 Inositol pyrophosphates, and methods of use thereof Ceased AU2003231157C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2009200042A AU2009200042A1 (en) 2002-04-29 2009-01-05 Inositol pyrophosphates, and methods of use thereof

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US37638302P 2002-04-29 2002-04-29
US60/376,383 2002-04-29
US38885102P 2002-06-14 2002-06-14
US60/388,851 2002-06-14
US39574902P 2002-07-12 2002-07-12
US60/395,749 2002-07-12
US42457302P 2002-11-07 2002-11-07
US60/424,573 2002-11-07
PCT/US2003/013105 WO2003092700A1 (en) 2002-04-29 2003-04-29 Inositol pyrophosphates, and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2009200042A Division AU2009200042A1 (en) 2002-04-29 2009-01-05 Inositol pyrophosphates, and methods of use thereof

Publications (3)

Publication Number Publication Date
AU2003231157A1 AU2003231157A1 (en) 2003-11-17
AU2003231157B2 AU2003231157B2 (en) 2008-10-09
AU2003231157C1 true AU2003231157C1 (en) 2009-02-26

Family

ID=29408059

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003231157A Ceased AU2003231157C1 (en) 2002-04-29 2003-04-29 Inositol pyrophosphates, and methods of use thereof
AU2009200042A Abandoned AU2009200042A1 (en) 2002-04-29 2009-01-05 Inositol pyrophosphates, and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2009200042A Abandoned AU2009200042A1 (en) 2002-04-29 2009-01-05 Inositol pyrophosphates, and methods of use thereof

Country Status (5)

Country Link
US (7) US7084115B2 (US07919481-20110405-C00020.png)
EP (1) EP1503768B1 (US07919481-20110405-C00020.png)
AU (2) AU2003231157C1 (US07919481-20110405-C00020.png)
CA (1) CA2488230C (US07919481-20110405-C00020.png)
WO (1) WO2003092700A1 (US07919481-20110405-C00020.png)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRE20010042A1 (it) * 2001-04-24 2002-10-24 Corghi Spa Dispositivo sollevatore per macchine smontagomme
FR2828206B1 (fr) * 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US20030232887A1 (en) * 2002-04-10 2003-12-18 Johnson Douglas Giles Preparation and use of a stable formulation of allosteric effector compounds
AU2003231157C1 (en) 2002-04-29 2009-02-26 Normoxys, Inc. Inositol pyrophosphates, and methods of use thereof
CA2563752A1 (en) 2004-04-22 2005-11-03 Allos Therapeutics, Inc. Compositions of allosteric hemoglobin modifiers and methods of making the same
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
KR101376895B1 (ko) 2004-05-03 2014-03-25 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
US20060106000A1 (en) * 2004-07-06 2006-05-18 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US20060241086A1 (en) * 2005-03-18 2006-10-26 Claude Nicolau Calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate as an allosteric effector of hemoglobin
US20070135389A1 (en) * 2004-07-06 2007-06-14 Claude Nicolau Tumor eradication by inositol-tripyrophosphate
US20120003161A1 (en) * 2004-07-06 2012-01-05 Normoxys, Inc. Use of inositol-tripyrophosphate in treating tumors and diseases
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US7745423B2 (en) * 2004-07-06 2010-06-29 NormOxys, Inc Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin
AU2006326283B2 (en) * 2005-12-12 2012-01-19 Ac Immune S.A. Therapeutic vaccine
EP1973398B1 (en) * 2006-01-06 2016-01-06 NormOxys, Inc. Use of inositol-tripyrophosphate in treating tumors mediated by angiogenesis
US20090311258A1 (en) * 2006-08-02 2009-12-17 Johannes Gutenberg-Universitaet Mainz Medicament for lct poisoning
EP2111226A4 (en) * 2006-12-29 2010-02-10 Normoxys Inc CYCLITOES AND THEIR DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
US20080312138A1 (en) * 2007-05-01 2008-12-18 Claude Nicolau Erythropoietin complementation or replacement
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
CA2725788A1 (en) * 2008-05-30 2009-12-03 Normoxys, Inc. Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
WO2010033878A2 (en) 2008-09-19 2010-03-25 David Brown Solute concentration measurement device and related methods
FR2944106B1 (fr) * 2009-04-03 2012-09-28 Erytech Pharma Methode de dosage de l'inositol hexaphosphate (ihp).
JP2012532879A (ja) * 2009-07-07 2012-12-20 ノームオキシーズ，インコーポレイテッド イノシトールトリピロリン酸を使用して多剤耐性を低減する方法
CA2921304C (en) 2009-07-30 2018-06-05 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
EP2968374A4 (en) * 2013-03-15 2016-08-10 Alphabet 3 Llc M METHODS AND COMPOSITIONS FOR IMPROVING OXYGEN RATE IN FABRICS
WO2015138916A1 (en) * 2014-03-14 2015-09-17 Yves Claude Nicolau Myo-inositol trispyrophoshate as an anti-diabetic agent
US20170021046A1 (en) * 2015-03-18 2017-01-26 Mojack Distributors, Llc Odor removal assembly
US10456360B2 (en) 2015-10-16 2019-10-29 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
EP3624885A4 (en) 2017-05-19 2021-03-10 Trudell Medical International POSITIVE EXPIRATORY PRESSURE DEVICE
USD903097S1 (en) 2018-05-18 2020-11-24 Trudell Medical International Mask
USD874064S1 (en) 2018-05-18 2020-01-28 Trudell Medical International Mask
USD893806S1 (en) 2018-11-09 2020-08-18 Trudell Medical Internationl Mask and shroud
CN109432410A (zh) * 2018-12-19 2019-03-08 上海康孕企业管理合伙企业（有限合伙） 血红素在预防和/或改善高原反应的药物、食品及保健食品中的应用
US11103628B1 (en) * 2020-04-29 2021-08-31 Orth Consulting, Llc Blood processing apparatus and method for detoxifying bacterial lipopolysaccharide
US10881781B1 (en) * 2020-04-29 2021-01-05 Orth Consulting, Llc Blood processing apparatus and method for detoxifying bacterial lipopolysaccharide

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US477134A (en) * 1892-06-14 Oyster-washing machine
JPS5858438B2 (ja) 1976-03-08 1983-12-24 三井東圧化学株式会社 コバルト−スズ合金メツキ浴
US4192869A (en) 1977-09-06 1980-03-11 Studiengesellschaft Kohle Mbh. Controlled improvement of the O2 release by intact erythrocytes with lipid vesicles
DE2740053A1 (de) 1977-09-06 1979-05-03 Klaus Prof Dr Med Gersonde Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten
JPS5828878B2 (ja) * 1980-08-20 1983-06-18 三金工業株式会社 環状ピロ燐酸エステル誘導体
US4473496A (en) 1981-09-14 1984-09-25 The United States Of America As Represented By The Secretary Of The Army Intramolecularly crosslinked hemoglobin
FR2529463B1 (fr) 1982-07-05 1986-01-10 Centre Nat Rech Scient Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus
US4473495A (en) 1983-07-28 1984-09-25 Northwestern University Albumin-solubilized hymenoptera venoms for vaccine use
US4478824A (en) 1983-08-08 1984-10-23 Franco Robert S Method for altering red blood cell function and survival
GB8328917D0 (en) * 1983-10-28 1983-11-30 Fisons Plc Blood substitute
US5330979A (en) 1984-10-23 1994-07-19 Perstorp Ab Method of treating renal disorders with inositoltriphosphate
US5545632A (en) 1984-10-23 1996-08-13 Perstorp Ab Method of treating retroviral disease
SE465951B (sv) 1984-10-23 1991-11-25 Perstorp Ab Isomer av inositoltrifosfat foeretraedesvis i saltform foer anvaendning som terapeutiskt eller profylaktiskt medel samt kompositioner daerav
SE465305B (sv) 1986-04-16 1991-08-26 Perstorp Ab Anvaendning av inositolfosfat foer framstaellning av ett laekemedel
US5407924A (en) 1984-10-23 1995-04-18 Perstorp Ab Method of treating pain using inositol triphosphate
US5015634A (en) 1986-04-16 1991-05-14 Perstorp Ab Method of treating tissue damage with inositol triphosphate
US5023248A (en) 1984-10-23 1991-06-11 Perstorp Ab Method of treating diabetes with inositol triphosphate
US4887995A (en) 1985-01-22 1989-12-19 University Of Pittsburgh Method of treating sickle cell anemia
US5292913A (en) * 1986-03-11 1994-03-08 Mitsui Toatsu Chemicals, Incorporated Myoinositol derivatives and preparation process thereof
DE3783694T2 (de) * 1986-03-11 1993-05-19 Mitsui Toatsu Chemicals Verfahren zur herstellung von myoinositolabkoemmlingen.
US4699926A (en) 1986-04-04 1987-10-13 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US4731381A (en) 1986-04-04 1988-03-15 Merck & Co., Inc. Method of treating a person for sickle cell anemia
US4731473A (en) 1986-04-04 1988-03-15 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US4751244A (en) 1986-04-04 1988-06-14 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US5135923A (en) 1986-04-16 1992-08-04 Perstorp Ab Method of treating cardiovascular diseases
US5057507A (en) 1986-04-16 1991-10-15 Perstorp Ab Method of alleviating bone damage with inositoltriphosphate
US4952396A (en) * 1986-11-19 1990-08-28 Linus Pauling Institute Of Science & Medicine Method of using phytic acid for inhibiting tumor growth
US5274161A (en) 1986-11-26 1993-12-28 Perstorp Ab Derivatives of cyclohexane
US4847082A (en) 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US4926023A (en) * 1987-04-24 1990-05-15 Nippon Kokan Kabushiki Kaisha High-speed rotative arc welding device
US4873355A (en) 1987-05-29 1989-10-10 E. I. Du Pont De Nemours And Company Process for regioselectively preparing phosphorylated inositols and other cyclitols
US4924023A (en) 1987-05-29 1990-05-08 E. I. Du Pont De Nemours And Company Phosphorylated inositols
US4931276A (en) * 1987-10-30 1990-06-05 Franco Robert S Method for introducing desired agents into red blood cells
JP2597618B2 (ja) 1987-12-28 1997-04-09 三井東圧化学 株式会社 光学分割方法
US5407926A (en) * 1987-12-29 1995-04-18 Alcon Laboratories, Inc. Ophthalmic composition
US4826675A (en) * 1988-02-17 1989-05-02 Colgate-Palmolive Company Anticalculus oral composition
US5043261A (en) 1989-04-10 1991-08-27 Cryopharm Corporation Lyophilized and reconstituted red blood cell and hemosome compositions
US5082833A (en) 1988-06-30 1992-01-21 Shamsuddin Abulkalam M Reduction of cell proliferation and enhancement of nk-cell activity
US4874690A (en) 1988-08-26 1989-10-17 Cryopharm Corporation Lyophilization of red blood cells
EP0392697A3 (en) 1989-04-12 1991-01-16 Petrolite Corporation Demulsifiers for resolving emulsions formed in the production of pharmaceuticals
US5264605A (en) * 1989-06-28 1993-11-23 Mitsui Toatsu Chemicals, Incorporated Myoinsitol derivatives, process for preparing same, phosphorylating agent, and its utilization
US5151539A (en) 1989-07-03 1992-09-29 Akzo America Inc. Formation of tetraarylpyrophosphate
US5091579A (en) * 1989-07-14 1992-02-25 Aristech Chemical Corporation Aniline catalyst
US5252707A (en) * 1989-09-22 1993-10-12 Mitsui Toatsu Chemicals Incorporated Inositol derivative and method for preparing same
JPH03115290A (ja) * 1989-09-28 1991-05-16 Yokohama Rubber Co Ltd:The １ｄ―ミオイノシトール―１―リン酸の合成法
US5173426A (en) 1989-10-06 1992-12-22 Yale University DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin
GB9001509D0 (en) * 1990-01-23 1990-03-21 Davy Mckee Poole An optical imaging device for guiding a robot
US5210263A (en) 1990-05-15 1993-05-11 University Of Pittsburgh Inositol phosphate analogs and methods for their use
WO1992020369A1 (en) 1991-05-14 1992-11-26 Dana Farber Cancer Institute Use of hemoglobin in a method for the treatment of tumors with chemotherapeutic agents
US5295944A (en) 1991-05-14 1994-03-22 Dana-Farber Cancer Institute Method for treating a tumor with ionizing radiation
JPH05210723A (ja) 1991-12-10 1993-08-20 Nec Corp 対話システムにおけるコマンド選択方式
US5260472A (en) 1992-01-29 1993-11-09 The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations Efficient chemoenzymatic synthesis of D-myo-inositol 1,4,5-triphosphate, D-myo-inositol 1,3,4-triphosphate, and D-myo-inositol 1,3,4,5-tetraphosphate
US5296466A (en) 1992-02-19 1994-03-22 Board Of Regents, The University Of Texas System Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
US5344393A (en) 1992-02-28 1994-09-06 Alliance Pharmaceutical Corp. Use of synthetic oxygen carriers to facilitate oxygen delivery
US5260287A (en) 1992-05-11 1993-11-09 Board Of Regents, The University Of Texas System Polyphosphorylated organic compounds: compositions useful in protecting biological tissues
US5691423A (en) 1992-08-24 1997-11-25 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-bound nitric oxide-nucleophile adducts
US5612207A (en) 1993-03-23 1997-03-18 Cbr Laboratories, Inc. Method and apparatus for encapsulation of biologically-active substances in cells
US5866548A (en) 1993-04-09 1999-02-02 The Regents Of The University Of California Caged membrane-permeant inositol phosphates
WO1995003068A1 (en) 1993-07-23 1995-02-02 The Upjohn Company Method for administering hemoglobin
US5827837A (en) 1993-08-20 1998-10-27 The Regents Of The University Of California Polyanion anti-inflammatory agents
SE502989C2 (sv) 1993-11-22 1996-03-04 Perstorp Ab Användning av en inositoltrisfosfatester för beredning av läkemedel
SE503122C2 (sv) 1993-11-22 1996-03-25 Perstorp Ab Användning av en inositoltrisfosfatester för behandling av inflammatoriska tillstånd
JPH08186151A (ja) * 1994-12-29 1996-07-16 Sony Corp 半導体装置及びその製造方法
US6074605A (en) 1995-03-10 2000-06-13 Entremed, Inc. Flow electroporation chamber and method
US5720921A (en) 1995-03-10 1998-02-24 Entremed, Inc. Flow electroporation chamber and method
US5626884A (en) 1995-08-18 1997-05-06 Lockett; Curtis G. Treatment of sickle cell disease
US6949517B1 (en) 1996-06-24 2005-09-27 Matti Siren Method of treating inflammatory, tissue repair and infectious conditions
US5699926A (en) * 1996-08-13 1997-12-23 Ipl, Inc. Five-piece container with stabilizer tablet
US5880099A (en) 1996-09-20 1999-03-09 The Regents Of The University Of California Inositol polyphosphates and methods of using same
US5977078A (en) 1996-09-20 1999-11-02 The Regents Of The Univesity Of California Inositol polyphosphate derivatives and methods of using same
DE19649350A1 (de) 1996-11-28 1998-06-04 Hoechst Ag Inositolglykane mit insulinartiger Wirkung
DE19649531A1 (de) * 1996-11-29 1998-06-04 Eastman Kodak Co Verstellbarer Fallschacht für Röntgenblattfilme
US6096916A (en) 1997-05-23 2000-08-01 Nutrimed Biotech Synthesis of D-3 phosphorylated phosphoinositides and analogues
JP4060913B2 (ja) 1997-09-09 2008-03-12 株式会社岡村製作所 椅子の背もたれ
US6187335B1 (en) 1997-12-31 2001-02-13 Orasomal Technologies, Inc. Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
AU6912500A (en) * 1999-08-25 2001-03-19 Gmp Companies, Inc. Enhanced oxygen delivery in mammals, methods and reagents related thereto
AU7101600A (en) 1999-09-02 2001-03-26 Rice University Nitric oxide-producing hydrogel materials
AU7995600A (en) 1999-10-05 2001-05-10 Theramed, Inc. Compositions and methods for the incorporation of chemical substances into cells
WO2001076572A2 (de) 2000-04-12 2001-10-18 bitop Aktiengesellschaft für biotechnische Optimierung Verwendung von kompatiblen soluten als substanzen mit radikalfangenden eigenschaften
US7084126B1 (en) 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
WO2002009723A2 (en) * 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of hemoglobin allosteric effectors, and uses thereof
US6610702B2 (en) 2000-08-01 2003-08-26 Gmp Oxycell, Inc. Ammonium salts of inositol hexaphosphate, and uses thereof
US7453006B2 (en) 2000-11-21 2008-11-18 Inologic, Inc. Inositol derivatives for increasing chloride secretion and inhibiting inflammation
EP1379275A4 (en) 2001-03-14 2005-12-21 Centocor Inc IMMUNOGLOBULIN-ASSOCIATED PROTEINS ASSOCIATED WITH OBSTRUCTIVE CHRONIC BRONCHOPNEUMOPATHY, COMPOSITIONS, METHODS AND USES
EP1435969A4 (en) 2001-09-20 2006-08-16 Inologic Inc METHOD FOR MODULATING THE ABSORPTION OF SODIUM IONS IN EPITHELIAL CELLS
AU2003231157C1 (en) * 2002-04-29 2009-02-26 Normoxys, Inc. Inositol pyrophosphates, and methods of use thereof
US20040072801A1 (en) 2002-06-14 2004-04-15 Nicolau Yves Claude Sterols bearing pendant allosteric effectors of hemoglobin, and uses thereof
CA2520291A1 (en) * 2003-03-27 2004-10-14 Inologic, Inc. Camphanylidene and phenylalkyl inositol polyphosphate compounds, compositions, and methods of their use
ES2232302B1 (es) * 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
US20070135389A1 (en) * 2004-07-06 2007-06-14 Claude Nicolau Tumor eradication by inositol-tripyrophosphate
US20060106000A1 (en) * 2004-07-06 2006-05-18 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US20060241086A1 (en) * 2005-03-18 2006-10-26 Claude Nicolau Calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate as an allosteric effector of hemoglobin
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
EP1973398B1 (en) 2006-01-06 2016-01-06 NormOxys, Inc. Use of inositol-tripyrophosphate in treating tumors mediated by angiogenesis

Also Published As

Publication number Publication date
US20110281825A1 (en) 2011-11-17
US20070207986A1 (en) 2007-09-06
WO2003092700A1 (en) 2003-11-13
AU2009200042A1 (en) 2009-02-05
US20060116358A1 (en) 2006-06-01
US7084115B2 (en) 2006-08-01
US7648970B2 (en) 2010-01-19
US20100256094A1 (en) 2010-10-07
US20130059820A1 (en) 2013-03-07
US7919481B2 (en) 2011-04-05
EP1503768B1 (en) 2015-10-28
CA2488230C (en) 2013-04-09
AU2003231157B2 (en) 2008-10-09
AU2003231157A1 (en) 2003-11-17
EP1503768A1 (en) 2005-02-09
US20040014642A1 (en) 2004-01-22
US8178514B2 (en) 2012-05-15
EP1503768A4 (en) 2009-10-21
US7618954B2 (en) 2009-11-17
US20140170127A1 (en) 2014-06-19
CA2488230A1 (en) 2003-11-13
US9078908B2 (en) 2015-07-14

Similar Documents

Publication Publication Date Title
AU2003231157C1 (en) Inositol pyrophosphates, and methods of use thereof
US20020142995A1 (en) Ammonium salts of hemoglobin allosteric effectors, and uses thereof
US6610702B2 (en) Ammonium salts of inositol hexaphosphate, and uses thereof
FI97891C (fi) Menetelmä 2'-deoksiguanosiinin asyylijohdannaisten valmistamiseksi
WO2001013933A2 (en) Agents for the enhanced oxygen delivery in mammals
EP1863495B1 (en) Calcium and sodium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate for treating cancer
US20130190524A1 (en) Cyclitols and their derivatives and their therapeutic applications
US20040072801A1 (en) Sterols bearing pendant allosteric effectors of hemoglobin, and uses thereof
US20100029594A1 (en) Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin
US7094557B2 (en) 2-Methyl-3-butenyl-1-pyrophosphoric acid salt and agent for treating lymphocytes
JP4135984B2 (ja) 医薬製剤
WO2009145751A1 (en) Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: OXYPLUS, INC.

Free format text: FORMER APPLICANT(S): GMP OXYCELL, INC.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 14 OCT 2008.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 14 OCT 2008

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE CO-PATENTEE NAME FROM UNIVERSITE LOUIS PASTEUR DE STRASBOURG TO UNIVERSITE DE STRASBOURG.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE CO-PATENTEE NAME FROM UNIVERSITE LOUIS PASTEUR DE STRASBOURG TO UNIVERSITE DE STRASBOURG

MK14 Patent ceased section 143(a) (annual fees not paid) or expired